INC. (NASDAQ:INCR) Files An 8-K Material Modification to Rights of Security HoldersItem 3.03
Material Modification to Rights of Security Holders.
The information set forth in Item 5.07 is incorporated by reference into this Item 3.03.
|
Item .0 |
Submission of Matters to a Vote of Security Holders. |
On August 23, 2018, in accordance with the applicable provisions of the Nevada Revised Statutes (the “NRS”), the Board of Directors (the “Board”) of All Soft Gels Inc. (the “Company”) unanimously adopted resolutions approving the following proposed actions (each, an “Action” and collectively, the “Actions”):
1.To change the name of the Company from All Soft Gels Inc. to Brain Scientific Inc.;
2.To increase the Company’s authorized shares of common stock from 50,000,000 to 200,000,000;
3.To create and authorize 10,000,000 shares of “blank check” preferred stock;
3.To adopt Amended and Restated Articles of Incorporation to incorporate the amendments described in actions (1), (2) and (3) above;
4.To change the Company’s ticker symbol; and
5.To adopt the Company’s 2018 Equity Incentive Plan, subject to certain conditions.
As of the close of business on August 23, 2018, to the applicable provisions of the NRS, the Company received a written consent approving the Actions from the holder of the common stock of the Company holding an aggregate of 6,000,000 shares of the common stock of the Company, representing a majority of the Company’s outstanding shares of voting capital stock.
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
